INTRODUCTION
============

Periprosthetic joint infection (PJI) after total hip arthroplasty (THA) is a devastating complication with infection rates varying from 0.5%-1.4% \[[@R1]\]. The standard of care for treatment of PJI has been two-stage revision arthroplasty with implantation of an antibiotic-impregnated cement spacer to eradicate the infection prior reimplantation. The cement spacer in the interim period can be classified as either a static/ non-articulating spacers (e.g. traditionally simple cement blocks) or a mobile/articulating spacer. The main goal of the spacer is to provide a local delivery of a high dose of antibiotics directly to the infection site. In addition, an articulating spacer has the advantage over a static spacer of allowing more comfortable motion between spaces, maintaning limb length, preventing contracture and increasing patient comfort during the interval prior to reimplantation.

In the recent years, the use of articulating cement spacers has become increasingly popular in both the hip and the knee following resection. Traditionally, antibiotic-loaded cement spacers have been performed by surgeons intraoperatively using a variety of technique ranging from hand-made techniques using a bulb syringe to fashion a femoral head, to molded systems with or wihtout a metal endo-skeleton to prevent fracture, to a sophisticated multi-size and multi-length spacer system with a large endo-skeleton and a constrained metal on polyethylene articulation to prevent both dislocation and fracture (PROSTALAC, DePuy, Warsaw, IN). However, in cases in which the infecting organisms are known preoperatively, prefabricated cement spacers (Spacer.G^®^ or InterSpace^®^ Hip) may be utilized.

In 2005, D´Angelo and colleagues performed a study comparing preformed and custom-made spacers with regards to functional outcomes and infection control in 20 patients \[[@R2]\]. The authors concluded, that preformed spacers were superior to custom-made spacer regarding functional outcome and complication rate, while the eradication rate was similar between both groups \[[@R2]\]. Since then, several authors have reported on the outcomes of preformed hip spacers (Spacer-G and InterSpace^®^ Hip) in the interim period of two-stage revision arthroplasty \[[@R3]-[@R2]\]. Many of these studies are small case series and it remains unclear if preformed hip spacers are superior to surgeon-made hip spacers in the treatment of periprosthetic joint infection following primary THA. Therefore, we performed this literature review to analyze the outcomes between surgeon-made and preformed articulating hip spacers in the treatment of infected total hip arthroplasty. The goal of the study is to find possible differences in the treatment of periprosthetic hip infection using preformed and surgeon-made spacers.

MATERIALS AND METHODS
=====================

We systematically reviewed the literature for potentially relevant articles addressing two-stage revision of an infected total hip arthroplasty using the MEDLINE computerized literature databases. Following keyword terms „total hip arthroplasty or total hip replacement" and „spacer or spacers" were used for initial search. The literature search was performed on May 1^st^ 2013 considering all published articles prior to May 1^st^ 2013. The initial search yielded 151 articles. Studies were inlcuded if they (1) described patients treated with surgeon-made and prefabricated/preformed articulating spacers following primary total hip arthroplasty; (2) reported reinfection rates; (3) reported Harris Hip Score after reimplantation and/or complication rates; and (4) follow-up examination of minimum 12 months. Review articles, case reports, letter to the editors or technical notes were excluded from the study. Studies using non-human subjects or *in vitro* studies including biomechanical studies and studies without the use of antibiotic spacers for two-stage revision for infected total hip arthroplasty were also excluded. A total of 43 articles met the inclusion and exclusion criteria and were included for the analyzes (Fig. **[1](#F1){ref-type="fig"}**). We excluded 35 case reports, 9 case series (n\<7), 7 technical notes, 12 review articles, 10 experimental studies and one brief communication. Furthermore, 15 studies reported on different functional outcomes (Merle d'Aubigné and Postel hip score, JOA hip score and WOMAC score) than HHS were also excluded. The remaining 17 articles were excluded due to follow-up examination of less than 12 months, reported outcomes in patients with fungal or multi-resistant periprothetic joint infection and patients treated without the use of antibiotic spacers for two-stage revision for infected total hip arthroplasty as well as reinfection cases after two-stage revision for infected THA.

The authors assessed the integrity of the study design and the research methods for each study. The level of evidence (level I-IV) was noted in every study according to the criteria set forth by the Oxford 2011 guidelines for level of evidence \[[@R13]\]. According to these guidelines, there were 3 level II, 4 level III and 36 Level IV studies (Tables**[1a](#T1a){ref-type="table"}** and **[1b](#T1b){ref-type="table"}**) \[[@R2]-[@R2],[@R14]-[@R46]\].

Data Analysis
-------------

All data regarding the methods and results of each of the articles included in the study were entered into a database and were analyzed. As available literature was heterogeneous and did not provide complete and quantitative information, a qualitative and descriptive summary of the results was compiled with regard to infection outcome, complication rate and functional outcome using the Harris Hip Score between preformed and surgeon-made hip spacers. Premade spacers are antibiotic-loaded preformed hip spacers. The inner part of the spacer usually contains a stainless steel rod, which is covered by antibiotic loaded cement. The cement is preloaded by the manufacturer most often with 1.9 g gentamicin sulfate \[[@R3]-[@R12]\]. Surgeon-made spacers are intraoperatively preformed spacers ranging from hand-made techniques using a bulb syringe to fashion a femoral head, to molded systems with or wihtout a metal endo-skeleton, while in the majority of cases, metal endoskeleton was not used.

RESULTS
=======

The analyzed studies included a total number of 1631 infected THA cases, 1027 treated with a surgeon-made spacers and 604 treated with preformed spacers (Fig. **[1](#F1){ref-type="fig"}**, Table **[1](#T1a){ref-type="table"}**). The mean follow-up for the surgeon-made and preformed groups was at 43.7 months (range, 15 to 144 months) and 48.9 months (range, 32 to 67 months), respectively (p=0.49). Likewise, the mean patient age was similar at 63.9 years (range, 52.6 to 73.9 years; SD=5.1) and 64.7 years (range, 55.7 to 71.8 years; SD=5.6) (p=0.58), respectively (Table **[1](#T1a){ref-type="table"}**). The mean time at follow-up examination (p=0.49) and the mean spacer duration between stages were also not significantly different (p=0.15) (Table **[1](#T1a){ref-type="table"}**).

Regarding functional outcome, we analyzed the preoperative Harris Hip Score and Harris Hip Scores at latest follow-up in the two groups. Similar improvement in Harris Hip Scores was observed in the two groups (Fig. **[2](#F2){ref-type="fig"}** and Table **[2](#T2){ref-type="table"}**). Preoperatively, there was no difference in the Harris Hip Score between the surgeon-made group and the premade group at 36.4 (range, 11.5 to 53) and 33.4 (range, 15 to 43.4), respectively (p=0.53). At lastest follow-up, the mean HHS was 84.3 (range, 68 to 97.8) for the surgeon-made spacers and 81.8 (range, 71.2 to 92.3) (p=0.5) for the preformed spacers. (Fig. **[2](#F2){ref-type="fig"}** and Table **[2](#T2){ref-type="table"}**). We are unable to comment on the HHS between stages because the majority of the studies did not report on this.

Looking at infection control, preformed hip spacers were also not superior to surgeon-made hip spacers in the treatment of infected THA (p=0.76). The eradication rate at latest follow-up after reimplantation was 94% using surgeon-made hip spacers and 94.5% using preformed hip spacers (Table **[2](#T2){ref-type="table"}**).

Complications
-------------

The overall spacer complication rate was similar between both groups (Tables **[3](#T3){ref-type="table"}** and **[4](#T4){ref-type="table"}**). However, the spacer fracture rate was significantly higher using surgeon-made hip spacers compared to the use of preformed hip spacers (Tables **[3](#T3){ref-type="table"}** and **[4](#T4){ref-type="table"}**) (p\<0.05).

DISCUSSION
==========

Two-stage revision arthroplasty for the treatment of chronic periprosthetic joint infection of the knee or hip joint infection is currently considered the universal gold standard. The type of spacer utilized during the interim period can be either an articulating or a static/non-articulating spacer. Articulating spacer has become increasingly more popular as it maintains limb length and patient function/comfort between stages following resection and facilitates the ease of reimplantation.

Historically, spacers have been surgeon made at the time of the operation. This allows for the selection of bacteria-specific antibiotics to be added to the spacer. In the recent years; however, the use of preformed or prefabricated articulating hip or knee spacers in the treatment of PJI has been increasing in some hospitals. These preformed spacers are preloaded with a set amount of antibiotics and preformed into the shape of the hip spacer. This has the potential to save time in the operating room and facilitates ease of reimplantation. However, Concerns have always remained regarding the amount of antibiotics in these preformed spacers as well as the cost associated with their use.

D´Angelo *et al*. reported superior outcome of preformed articulating spacers compared to custom-made spacers regarding functional outcome and complication rate, while the eradication rate was similar between both groups \[[@R2]\]. Since then, several authors reported on the outcomes using those preformed hip spacers (Spacer-G and InterSpace^®^ Hip) in the interim period of two-stage revision arthroplasty \[[@R3]-[@R12]\]. Most of the studies are limited due to a small number of included cases or due to a relatively short follow-up time. We therefore performed this analysis to compare the results using preformed and surgeon-made articulating hip spacers in the treatment of PJI.

In contrast to the study by D´Angelo and colleagues, our analysis of large series of both prefabricated and surgeon made spacers showed no differences regarding functional outcome. The analyzed HHS (preoperative HHS and HHS at latest follow-up) were comparable in both groups and as also reported by D´Angelo *et al*., the eradication rate was similar between both types of spacers. It must be noted that, we are unable to comment on the HHS between stages because the majority of the studies did not report on this.

In addition, our analysis showed a significantly higher spacer fracture rate in the surgeon made fracture group compared to the preformed spacer group. It seems that surgeon made spacers tend to fail in a more "agressive" way than preformed ones. This might be based on the "ratherinhomogenous" way of cement mixing and delivery during spacer preparation and application into the situs. In addition, the combination of high dose antibiotics mixing might counteract the mechanical stabilty. The higher fracture rate might be due to the absence of a metal endo-skeleton of sufficient strength.

The exception is the PROSTALAC system, which has not had a single report of implant fracture due to the robust nature of its metal endoskleton and its sophisticated molding system. It should also be noted that while not statistically significant, the preformed spacers had a higher dislocations rate. These preformed spacers may limit the ability of the surgeon to control leg length and offset thus potentially putting patients at risk for instability in the interim stage.

Our study has important limitations. First of all, as with all systematic reviews and/or meta-analyses, the study is limited by the inherent weaknesses of the component studies. Most of the included studies are Level-IV studies characterized by retrospective study designs, limited population sizes, and short- to medium-term follow-up time intervals. Interestingly, none of the included studies were level I or level II studies. Possible reasons of not existing of studies with high level of evidence could be that the technique is often based on surgeons preference and the general availability of pre-formed spacers in each country/region and the definition of clear contraindication for articulating spacers.

It must also be noted that, we did not control for confounding variables such as comorbidities, body mass index and the infecting organism. Although our study showed a significantly higher rate of fracture for the surgeon made spacer, it should be noted that there can be significant variation in the way the spacers are fabricated among surgeons and this study could not account for those technical differences. For example, some surgeons may choose to utilize the metal endoskeleton to reinforce the cement spacer, and this will minimize the fracture risk.

Despite the drawbacks, our study makes important comp-arisons between preformed and surgeon-made articulating hip spacers regarding infection control, functional outcomes following reimplantation and complication rates.

In conclusion, our results present no differences regarding infection control and functional outcome at latest follow-up using preformed or surgeon-made articulating hip spacers in the treatment of PJI. However, it must be noted that the spacer fracture rate was higher using intraoperative surgeon-made spacers. Nevertheless, the use of more costly preformed articulating hip spacers should be scrutinized.

Furthermore, our study shows the necessity of larger prospective, randomized controlled trials to further elucidate the superiority for periprosthetic joint infection following total hip arthroplasty.
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###### 

Included studies with surgeon-made articulating hip spacers in the treatment of PJI.

  Author         Year of Publication   Number of Cases   Follow-Up      Number of Reinfections   Eradication Rate(%)
  -------------- --------------------- ----------------- -------------- ------------------------ ---------------------
  Borowski       2012                  29                not reported   3                        89,7
  Ben-Lulu       2012                  11                15             1                        90,9
  Fleck          2011                  14                46,3           1                        92,9
  Zou            2011                  15                25             0                        100,0
  Fei            2011                  51                61,4           0                        100,0
  Peng           2011                  34                not reported   0                        100,0
  Liu            2010                  107               34,3           6                        94,4
  Peng           2010                  15                31,2           0                        100,0
  Dairaku K      2009                  10                18             1                        90,0
  Biring         2009                  99                144            11                       88,9
  Jung           2009                  88                54             10                       88,6
  Kent           2010                  15                38             0                        100,0
  Whittaker JP   2009                  41                49             3                        92,7
  Fink           2009                  36                35             0                        100,0
  Toulson        2009                  84                64,8           4                        95,2
  McKenna        2009                  31                35             0                        100,0
  lncavo         2009                  12                24             2                        83,3
  Diwanji        2008                  9                 42             2                        77,8
  Masri          2007                  29                47             3                        89,7
  D\'Angelo      2005                  8                 40             1                        87,5
  Hoffmann       2005                  27                76             1                        96,3
  Morshed        2005                  13                42,6           3                        76,9
  Durbhakula     2004                  20                38             0                        100,0
  Hsieh          2004                  58                not reported   2                        96,6
  Hsieh          2004                  42                55,2           2                        95,2
  Jahoda         2004                  11                not reported   0                        100,0
  Yamamoto       2003                  17                38             0                        100,0
  Takahira       2003                  9                 35,7           1                        88,9
  Koo            2001                  22                41             1                        95,5
  Lsiklar        1999                  10                23,4           0                        100,0
  Leunig         1998                  12                27             1                        91,7
  Younger        1997                  48                43             3                        93,8

###### 

Included studies with preformed articulating hip spacers.

  Author         Year of Publication   Number of Cases   Follow-Up (Months)   Number of Reinfections   Eradication Rate(%)
  -------------- --------------------- ----------------- -------------------- ------------------------ ---------------------
  Romano         2012                  183               60                   10                       94,5
  Degen          2012                  33                43                   5                        84,8
  Neumann        2012                  44                67                   1                        97,7
  Romano         2011                  20                56,6                 1                        95,0
  D\'Angelo      2011                  28                53                   1                        96,4
  Pattyn         2011                  61                36                   2                        96,7
  Romano         2010                  40                52,1                 1                        97,5
  Pignatti       2010                  41                63,6                 0                        100,0
  Gil Gonzalez   2010                  35                32                   5                        85,7
  Romano         2010                  102               48                   4                        96,1
  D\'Angelo      2005                  12                40                   1                        91,7
  Magnan         2001                  10                35                   2                        80,0

###### 

Descriptive information of surgeon-made and preformed hip spacer studies. \*NC = not calculated. †Significant (p \< 0.05).

  Variable                        Surgeon Made Spacers (Range)   Preformed Spacers (Range)   p Value
  ------------------------------- ------------------------------ --------------------------- ---------
  No. of cases                    1027                           604                         NC
  Mean Age (years)                63.9 (52.6-73.9)               64.7 (55.7-71.8)            0.58
  Mean spacer duration (months)   5,6 (3-9.4)                    4.4 (2.9-5.6)               0.15

###### 

Clinical data reported in the analyzed studies. †Significant (p \< 0.05).

  Variable                   Surgeon Made Spacers (Range)   Preformed Spacers (Range)   p Value
  -------------------------- ------------------------------ --------------------------- ---------
  Mean follow-up (months)    43.7 (15-144)                  48.9 (32-67)                0.49
  Reinfection rate           6.0%                           5.5%                        0.76
  Preoperative HSS score     36.4 (11.5-53)                 33.4 (15-43.4)              0.53
  Postoperative HSS score    84.3 (68-97.8)                 81.8 (71.2-92.3)            0.50
  Spacer complication rate   12.9%                          12.4%                       \>0.05

###### 

Detailed information about the complications related to the surgeon-made and preformed cement hip spacers. †Significant (p \< 0.05).

  Variable             Surgeon Made Spacers   Preformed Spacers   p Value
  -------------------- ---------------------- ------------------- ---------
  Spacer dislocation   7.0%                   12.4%               0.13
  Spacer fracture      5.9%                   0%                  \>0.05
